Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlling the complement system for prevention of red cell destruction.

Karina Yazdanbakhsh1

  • 1Complement Biology, New York Blood Center, New York, NY 10021, USA. kyazdanbakhsh@nybloodcenter.org

Current Opinion in Hematology
|February 24, 2005
PubMed
Summary

Complement inhibitors offer promising treatments for red blood cell destruction and autoimmune hemolytic anemia. These therapies target complement activation, potentially preventing hemolysis and improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting erythroid cell-derived asparagine inhibits alloimmunization in sickle cell disease.

Blood advances·2026
Same author

Effect of sildenafil on platelet activation and mediators of vascular remodelling during LVAD support.

ESC heart failure·2026
Same author

Warm autoimmune haemolytic anaemia: Clinical considerations.

British journal of haematology·2026
Same author

Heme-induced activation of the TLR3/TRIF-IFN-I-CCL2 pathway contributes to kidney injury in sickle cell disease.

Blood·2026
Same author

Safety and efficacy of combined heparin/citrate anticoagulation for cell therapy collections in healthy adult allogeneic donors.

Transfusion·2025
Same author

HCAR2 the rescue: sensing heme, steering inflammation.

Blood advances·2025

Area of Science:

  • Immunology
  • Hematology
  • Drug Discovery

Background:

  • Complement sensitization of red blood cells (RBCs) causes hemolysis.
  • Dysregulation of complement regulatory proteins on RBCs or immune cells leads to RBC destruction and autoimmune diseases.

Purpose of the Study:

  • To review complement inhibitors for treating complement-mediated RBC destruction.
  • To discuss the role of complement in autoimmune hemolytic anemia.

Main Methods:

  • Review of existing literature on complement inhibitors.
  • Analysis of complement cascade pathways and regulatory proteins.
  • Evaluation of therapeutic applications for hemolytic diseases.

Main Results:

  • Several complement inhibitors (recombinant proteins, antibodies, synthetic molecules) are available.

Related Experiment Videos

  • Few inhibitors have been tested for preventing complement-mediated RBC destruction.
  • Complement inhibitors show potential for treating specific hemolytic diseases.

    • Conclusions:

    • Complement therapeutics can be used prophylactically and therapeutically for hemolytic transfusion reactions and complement-mediated hemolytic diseases.
    • The regulatory role of complement can be leveraged to treat autoimmune hemolytic anemia.